News

FDA Bureaucrats Unlawfully Delay Hearing on Vanda Drug and Falsely Blame Commissioner Makary and the reductions in force at FDA
Vanda Pharmaceuticals Inc. ("Vanda") (Nasdaq: VNDA) today announced that FDA bureaucrats have committed to delay Vanda's ...
Fierce Biotech1d
Vanda sues FDA over hearing delay as agency points to mass layoffs, other litigation with the biopharma
Vanda Pharmaceuticals is suing the FDA again, this time alleging the agency is unlawfully delaying a hearing to discuss the ...
Vanda Pharmaceuticals Announces Presentation at 2025 AAN Annual Meeting
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced participation at the American Academy of Neurology (AAN) Annual Meeting, to be held in San Diego, California from April 5 through ...
BioSpace10d
Vanda Sues FDA Again, This Time Over Off-Label Use of Hetlioz for Jet Lag
Vanda is criticizing the FDA’s restrictions on information companies can provide regarding off-label use of approved ...
Fierce Pharma13d
After Hetlioz's rejection in jet lag disorder, Vanda sues FDA for right to promote off-label use
After years of back-and-forth with the FDA over Hetlioz's potential use as a jet lag disorder treatment, Vanda ...
Vanda Pharmaceuticals submits NDA to FDA for Bysanti
Vanda Pharmaceuticals (VNDA) announced that a New Drug Application was submitted to the U.S. FDA requesting marketing approval of Bysanti for ...
The Victoria Advocate18d
Vanda Pharmaceuticals Announces Presentation at 2025 AAN Annual Meeting
For more information on the AAN Annual Meeting, please refer to www.aan.com. About Vanda Pharmaceuticals Inc. Vanda is a leading global biopharmaceutical company focused on the development and ...